

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL EL 990504539 US

No.:

APPLICANT(s): MAUL et al.

SERIAL NO.: ART UNIT:

FILING DATE: Herewith EXAMINER:

TITLE: USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS  
PHARMACEUTICAL PREPARATIONS

ATTORNEY

DOCKET NO.: 785-011642-US (C01)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

(37 C.F.R. §1.97(b)(1))

Sir:

This Information Disclosure Statement is filed together with the above-identified patent application. Thus, a certification under 37 C.F.R. 1.97 (e) or fee under 37 C.F.R. 1.17(p) is not required for the information herein to be considered.

The following information is being disclosed to the Patent and Trademark Office as information that may be

material to the examination of the above-identified patent application.

The above-identified patent application claims priority to German Patent Application No. 10132726.9 filed July 5, 2001 and claims the benefit of PCT International Application No. PCT/EP02/07382 filed July 3, 2002. Applicants' attorney encloses a copy of a German Search Report issued on the priority German Patent Application No. 10132726.9 and a PCT International Search Report issued on the corresponding PCT International Application No. PCT/EP02/07382. The German Search Report cited German Patent Application No. DE 10050663A1 and PCT International Publication No. WO 01/27109A2. The PCT International Search Report cited PCT International Publication No. WO 91/02725 A and "Discovery of Some of the Biological Effects of Nitric Oxide and Its Role in Cell Signalling (Nobel Lecture)", Murad, Angewandte Chemie. International Edition, Verlag Chemie. 38, 1999, pp. 1857-1868.

Applicants' attorney also encloses a copy of "Nitric Oxide Synthase Inhibition In Migraine", Lassen et al., The Lancet, Vol. 349, 1997, pp. 401-402, which was cited in the specification of the above-identified patent application.

Pursuant to Sections 609 and 707.05(b) of the MPEP and 37 C.F.R. 1.97-1.99, the undersigned is bringing the following co-pending U.S. patent applications of which he is aware, to the attention of the Examiner in the above-identified application as they may be considered pertinent to the invention claimed in the above-identified application.

(1) Express Mail No.: EL 990504542 US  
Mailing Date: January 5, 2004  
Title: Substituted 1-Aryl-But-3-Enylamine  
And 1-Aryl-But-2-Enylamine Compounds  
Assignee: Grunenthal GmbH et al.  
Attorney Docket No.: 785-011630-US (C01)

(2) Express Mail No.: EL 990504794 US  
Mailing Date: January 5, 2004  
Title: Substituted  $\gamma$ -Lactone Compounds As  
NMDA-Antagonists  
Assignee: Grunenthal GmbH  
Attorney Docket No.: 785-011640-US (C01)

(3) Express Mail No.: EL 990504803 US  
Mailing Date: January 5, 2004  
Title: Substituted 1-Phenethylpiperidine  
Compounds Used As Inter Alia Analgesics  
Assignee: Grunenthal GmbH  
Attorney Docket No.: 785-011641-US (C01)

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any additional fees associated with this

communication or credit any over payment to Deposit  
Account No. 16-1350.

Respectfully submitted,



Clarence A. Green

  
\_\_\_\_\_  
Date

Reg. No.: 24,622

PERMAN & GREEN, LLP

425 Post Road, Fairfield, CT 06824

(203) 259-1800

Customer No.: 2512

<b>INFORMATION DISCLOSURE CITATION FORM FOR PATENT APPLICATION (FORM PTO-1449) (Substitute)</b>		Docket No.: 785-011642-US (CO1)		Serial No.: Applicant(s): MAUL et al.		
				Filing Date: Herewith	Group:	
<b>U.S. PATENTS</b>						
Initials	Patent Number	Issue Date	Name		Class	Sub-class
<b>U.S. PATENT PUBLICATIONS</b>						
Initials	Publication No.	Pub. Date	Name		Class	Sub-class
<b>FOREIGN PATENT DOCUMENTS</b>						
Initials	Document Number	Date	Country		Name	
	WO 01/27109 A2	04/19/01	PCT	Grünenthal GMBH		Translation? Yes/No/n/a
	WO 91/02725	03/07/91	PCT	Syntheses et Recherches		No
	100 50 663 A 1	04/18/02	Germany	Grünenthal GMBH		No
<b>OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)</b>						
	"Discovery of Some of the Biological Effects of Nitric Oxide and Its Role in Cell Signaling (Nobel Lecture)", Ferid Murad, Angew. Chem. Int. Ed. 1999, 38, pp. 1857-1868.					
	"Nitric Oxide Synthase Inhibition In Migraine", Lassen et al., The Lancet, 1988, Vol. 349, pp.401 – 402					
Examiner's Signature:				Date Considered:		
Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered. Include a copy of this citation form with your next correspondence to the Applicant(s).						